source
- Cytokinetics heart drug scores in closely watched trialMyqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.BioPharma Dive · 3mo ago↗ source
- What you need to know about hantavirus (don’t panic)The latest on the abortion pill, paternal deaths, and more health news from Morning RoundsSTAT · 3mo ago↗ source
- Cytokinetics succeeds where Bristol Myers failed in heart muscle diseaseCytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…Endpoints · 3mo ago